Aktienanalyse zu MeiraGTx Holdings PLC (MGTX)MGTXMeiraGTx Holdings PLC

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company. It has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

MeiraGTx Holdings PLC is currently not a strong buy. The stock is trading at $9.21, significantly below the analyst price targets of $16 and $26, indicating potential upside. However, the RSI is at 30.872, suggesting the stock is oversold, which could indicate a buying opportunity, but the forward P/E ratio is high at 64.1026, indicating potential overvaluation. The main risk is the recent insider selling and the uncertainty surrounding regulatory approvals, which could impact stock performance.

3 analysts cover MGTX: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 21.50.